Hospitalised low-risk community-acquired pneumonia: Outcome and potential for cost-savings

Annals of the Academy of Medicine Singapore

Volumn 28, Issue 3, 1999, Pages 389-391

  Lee, Kang Hoe ^a   Chin, N K ^b   Tan, W C ^b   Lim, T K ^b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NONE

Author keywords

Hospitalisation; Intensive care unit; Mortality

Indexed keywords

AGED; ARTICLE; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; COMPARATIVE STUDY; COST CONTROL; ECONOMICS; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MIDDLE AGED; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RISK FACTOR; SINGAPORE; STATISTICS;

AGED; COMMUNITY-ACQUIRED INFECTIONS; COST SAVINGS; HOSPITAL CHARGES; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; RISK FACTORS; SINGAPORE;

EID: 0033130156     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Garibaldi R A. Epidemiology of community-acquired respiratory tract infections in adults: incidence, etiology, and impact. Am J Med 1985; 78:32-7.
2. La Force F M. Community-acquired lower respiratory tract infections: prevention and cost-control strategies. Am J Med 1985; 78:52-7.
3. Blaser M J, Klaus B D, Jacobson J A, Kasworm E, LaForce F M. Comparison of cefadroxil and cephalexin in the treatment of community-acquired pneumonia. Antimicrob Agents Chemother 1983; 24:163-7.
4. Fine M J, Auble T E, Yealy D M, Hanusa B H, Weissfeld L A, Singer D E, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-50.
5. Wunderink R G. Clinical practice guidelines for the management of pneumonia - do they work? New Horizons 1998; 6:75-83.
6. Fine M J, Smith M A, Carson C A, Mutha S S, Sankey S S, Weissfeld L A, et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 1995; 274:134-41.
7. Eee K H, Hui K P, Tan W C, Lim T K. Severe community-acquired pneumonia in Singapore. Singapore Med J 1996; 37:374-7.
8. Cunha B A. Community-acquired pneumonia. Cost-effective antimicrobial therapy. Postgrad Med 1996; 99:109-22.
9. Siegel R E, Halpern N A, Almenoff P L, Lee A, Cashin R, Greene J G. A prospective randomized study of inpatient iv antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996; 110: 965-71.
10. Neiderman MS, Bass J B, Campbell G D, Fein AM, Grossman R F, Mandell L A, et al. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993; 148:1418-26.
11. Gleason P P, Kapoor W N, Stone R A, Lave J R, Obrosky S, Schulz R, et al. Medical outcome and antimicrobial costs with the use of the American Thoracic Society Guidelines for outpatients with community-acquired pneumonia. JAMA 1997; 278:32-9.
12. Guest J F, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997; 10:1530-4.
13. Lave J R, Fine M J, Sankey S S, Hanusa B H, Weissfeld L A, Kapoor W N. Hospitalized pneumonia. Outcomes, treatment patterns, and costs in urban and rural areas. J Gen Intern Med 1996; 11:415-21.
14. Fine M J, Hough L J, Medsger A R, Li Y H, Ricci E M, Singer D E, et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia patient outcomes research team cohort study. Arch Intern Med 1997; 157:36-44.